Eli Lilly and Company’s Neuroscience Research Chief Resigns
Wall Street Journal -- LONDON (Dow Jones)--Shire PLC (SHP.LN), a global specialty biopharmaceutical company, said Monday it has submitted a complete response to the not approvable letter issued by the U.S. Food and Drug Administration, or FDA, to Jerini AG in April 2008 regarding its New Drug Application for FIRAZYR (icatibant) for the treatment of acute attacks of hereditary angioedema, or HAE.